News
-
-
COMMUNIQUÉ DE PRESSE
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemer. European Patent Office grants Napo Pharmaceuticals patent to use crofelemer for congenital diarrheal disorders (CDDs). Jaguar supports studies in SBS and MVID, with results by 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Jaguar Health, Inc. announces initial results from Phase 3 OnTarget trial of crofelemer for cancer patients' diarrhea prophylaxis. Positive signals for breast and respiratory cancer subgroups in multicenter, double-blind study -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Jaguar Health announces webcast for cancer supportive care updates including OnTarget trial results. Make Cancer Less Shitty program expands with MCLS Ambassadors -
-
